Dechra targets ophthalmic conditions with new ointment Ophtocycline®

dinsdag 6 augustus 2019

A new treatment to tackle specific eye ailments in dogs, cats and horses has been launched by Dechra Veterinary Products.

Ophtocycline^®, which has the active ingredient chlortetracycline hydrochloride, is a broad spectrum ophthalmic antibiotic ointment in a paraffin base for the treatment of keratitis, conjunctivitis and blepharitis caused by Staphylococcus spp., Streptococcus spp., Proteus spp., and/or Pseudomonas spp.

Chlortetracycline hydrochloride works against both aerobic and anaerobic Gram-negative and Gram-positive bacteria. The recommended dosage is four times a day for five days. The 10 mg/g ophthalmic ointment has a 14-day broached shelf life. There is a one-day withdrawal period for meat and offal.

Dechra Brand Manager Carol Morgan said: “Ophtocycline provides veterinary professionals with a targeted treatment to effectively tackle the growing and reproducing bacteria that causes these eye conditions.

“Chlortetracycline is a bacteriostatic antibiotic which interferes with bacterial protein synthesis in the rapidly growing and reproducing bacterial cell and has both time-dependent and concentration dependent effects.

“We are very pleased to be able to roll out this product to the market as part of our ophthalmic range alongside popular products such as Isathal^®.”